Luke Slade, Shelby E Bollen, Joseph J Bass, Bethan E Phillips, Kenneth Smith, Daniel J Wilkinson, Nathaniel J Szewczyk, Philip J Atherton, Timothy Etheridge
BACKGROUND: Age-related muscle decline (sarcopenia) associates with numerous health risk factors and poor quality of life. Drugs that counter sarcopenia without harmful side effects are lacking, and repurposing existing pharmaceuticals could expedite realistic clinical options. Recent studies suggest bisphosphonates promote muscle health; however, the efficacy of bisphosphonates as an anti-sarcopenic therapy is currently unclear. METHODS: Using Caenorhabditis elegans as a sarcopenia model, we treated animals with 100 nM, 1, 10, 100 and 500 μM zoledronic acid (ZA) and assessed lifespan and healthspan (movement rates) using a microfluidic chip device...
September 18, 2023: Journal of Cachexia, Sarcopenia and Muscle